Primary Immunodeficiency Disorders Market Report 2026

The primary immunodeficiency disorders market size has grown strongly in recent years. It will grow from $7.3 billion in 2025 to $7.79 billion in 2026 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to improved clinical recognition of immunodeficiency disorders, expansion of diagnostic testing capabilities, rising awareness among healthcare professionals, availability of immunoglobulin therapies, growth of specialized treatment centers.

The primary immunodeficiency disorders market size is expected to see strong growth in the next few years. It will grow to $10.01 billion in 2030 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to increasing advancements in gene therapy research, rising demand for early and accurate diagnosis, expansion of precision immunology treatments, growing investment in rare disease research, increasing integration of ai in diagnostic workflows. Major trends in the forecast period include increasing adoption of genetic testing for early diagnosis, growing use of immunoglobulin replacement therapies, rising focus on personalized treatment approaches, expansion of newborn screening programs, enhanced integration of advanced diagnostic platforms.

The increasing prevalence of autoimmune diseases is expected to drive the growth of the primary immunodeficiency disorders market in the coming years. Autoimmune diseases arise when the immune system incorrectly attacks healthy cells and tissues in the body, perceiving them as foreign threats. This abnormal immune response results in inflammation and damage across different organs and systems. The rise in autoimmune conditions is linked to a combination of environmental factors, genetic susceptibility, and lifestyle changes. Autoimmune diseases can contribute to primary immunodeficiency disorders by impairing immune regulation and damaging immune cells, leading to weakened or dysfunctional immune responses. For instance, in February 2024, according to Arthritis Australia, an Australia-based charitable not-for-profit organization supporting people with arthritis and musculoskeletal conditions, approximately 562,378 Australians are projected to be living with rheumatoid arthritis by 2025, representing 14% of the total arthritis population. Therefore, the increasing prevalence of autoimmune diseases is contributing to the growth of the primary immunodeficiency disorders market.

The growing emphasis on preventive care is expected to further propel the growth of the primary immunodeficiency disorders market going forward. Preventive care includes healthcare services and interventions focused on disease prevention, early detection of health conditions, and the promotion of overall health and well-being. The importance of preventive care is increasing due to greater awareness of early disease identification, which helps reduce serious health complications and lowers long-term healthcare costs. Primary immunodeficiency disorders underscore the value of preventive care by showing that early diagnosis and proactive management can help prevent severe infections and complications, reinforcing the need for routine screening and immunological monitoring. For instance, in March 2024, according to a report by the Government of the United Kingdom, a UK-based information website, the proportion of people with type 1 diabetes in England receiving all eight care processes at GP practices participating in the NDA rose to 43.8% in March 2023, up from 35.2% the previous year. Therefore, the increasing focus on preventive care is driving the growth of the primary immunodeficiency disorders market.

Major companies operating in the primary immunodeficiency disorders market are concentrating on the development of advanced therapies, such as intravenous immunoglobulin therapy, to improve patient outcomes by strengthening immune function. Intravenous immunoglobulin (IVIG) therapy involves the administration of immunoglobulins, or antibodies, derived from donor plasma directly into a patient’s bloodstream through intravenous infusion. For instance, in June 2024, Grifols, a Spain-based healthcare company, received FDA approval for Yimmugo, an intravenous immunoglobulin therapy. This newly developed, sugar-free, ready-to-use IgG solution is sourced from human blood plasma and is designed for intravenous use. Approved in the United States for substitution therapy in patients with primary antibody deficiency syndromes, Yimmugo provides antibody replacement to support individuals with immune system deficiencies. It expands Grifols’ portfolio of plasma-derived treatments by offering a safer and more effective option to help protect patients against infections.

Major companies operating in the primary immunodeficiency disorders market are Pfizer Inc, Takeda Pharmaceuticals, CSL Behring, Baxter International Inc, Grifols SA, Octapharma, Kedrion Biopharma, LFB Group, ADMA Biologics Inc, Bio Products Laboratory Ltd, Miltenyi Biotec, BD Biosciences, Cellectis SA, X4 Pharmaceuticals Inc, bluebird bio Inc, Chengdu Rongsheng Pharmaceutical Co Ltd, Sanofi SA, Roche Holding AG, Novartis AG, AbbVie Inc, AstraZeneca plc, Gilead Sciences Inc.

North America was the largest region in the primary immunodeficiency disorders market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary immunodeficiency disorders market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the primary immunodeficiency disorders market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the primary immunodeficiency disorders market by increasing costs of imported diagnostic reagents, genetic testing kits, immunoglobulin products, and specialized laboratory equipment required for diagnosis and treatment. Hospitals and specialty clinics in North America and Europe are most affected due to reliance on imported biologics and diagnostic technologies, while Asia-Pacific faces higher treatment costs for advanced therapies. These tariffs are raising overall treatment expenses and affecting patient access in some regions. However, they are also encouraging domestic biologics manufacturing, regional diagnostic capacity building, and investment in local rare disease research ecosystems.

The primary immunodeficiency disorders market research report is one of a series of new reports that provides primary immunodeficiency disorders market statistics, including primary immunodeficiency disorders industry global market size, regional shares, competitors with a primary immunodeficiency disorders market share, detailed primary immunodeficiency disorders market segments, market trends and opportunities, and any further data you may need to thrive in the primary immunodeficiency disorders industry. This primary immunodeficiency disorders market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Primary immunodeficiency disorders (PIDs) are inherited conditions that weaken or disrupt the immune system, leading to increased susceptibility to infections, autoimmune conditions, and certain types of cancer. Early identification and diagnosis of primary immunodeficiency disorders are essential for initiating timely treatment, preventing infections, and improving patient quality of life through therapies such as immunoglobulin replacement or bone marrow transplantation.

The key disease categories within primary immunodeficiency disorders include antibody deficiency, cellular immunodeficiency, innate immune disorders, and others. Antibody deficiencies occur when the immune system is unable to produce sufficient antibodies, which are proteins that recognize and neutralize harmful pathogens. Treatment options include immunoglobulin replacement therapy, antibiotic therapy, stem cell and bone marrow transplantation, gene therapy, and others. Diagnostic approaches involve genetic testing, blood tests, flow cytometry, and additional methods, and these are applied across hospitals, specialty clinics, homecare environments, and research institutions.

The primary immunodeficiency disorders market consists of revenues earned by entities by providing services such as immunoglobulin therapy, rehabilitation and support programs, educational and advocacy services, and personalized treatment plans. The market value includes the value of related goods sold by the service provider or included within the service offering. The primary immunodeficiency disorders market also includes sales of vaccines, antibiotics, antifungals, and small molecule drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.